Royalty Pharma (RPRX) Loans and Notes Receivables (2019 - 2025)
Historic Loans and Notes Receivables for Royalty Pharma (RPRX) over the last 7 years, with Q4 2025 value amounting to $854.4 million.
- Royalty Pharma's Loans and Notes Receivables rose 900.98% to $854.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $854.4 million, marking a year-over-year increase of 900.98%. This contributed to the annual value of $854.4 million for FY2025, which is 900.98% up from last year.
- Per Royalty Pharma's latest filing, its Loans and Notes Receivables stood at $854.4 million for Q4 2025, which was up 900.98% from $860.1 million recorded in Q3 2025.
- In the past 5 years, Royalty Pharma's Loans and Notes Receivables registered a high of $860.1 million during Q3 2025, and its lowest value of $522.4 million during Q1 2021.
- Moreover, its 5-year median value for Loans and Notes Receivables was $703.9 million (2022), whereas its average is $697.3 million.
- Per our database at Business Quant, Royalty Pharma's Loans and Notes Receivables soared by 1657.81% in 2022 and then soared by 276.58% in 2024.
- Royalty Pharma's Loans and Notes Receivables (Quarter) stood at $614.4 million in 2021, then increased by 12.53% to $691.3 million in 2022, then rose by 6.82% to $738.4 million in 2023, then increased by 6.14% to $783.8 million in 2024, then increased by 9.01% to $854.4 million in 2025.
- Its Loans and Notes Receivables was $854.4 million in Q4 2025, compared to $860.1 million in Q3 2025 and $842.9 million in Q2 2025.